Viruses are very small organisms; most can’t even be seen with an ordinary microscope. They are made up of a small number of genes in the form of DNA or RNA surrounded by a protein coating. A virus must enter a living cell and take over the cell’s machinery in order to reproduce and make more viruses. Some viruses do this by inserting their own DNA (or RNA) into that of the host cell. When the DNA or RNA affects the host cell’s genes, it can push the cell toward becoming cancer.
In general, each type of virus tends to infect only a certain type of cell in the body. (For example, the viruses that cause the common cold only infect the cells lining the nose and throat.)
Several viruses are linked with cancer in humans. Our growing knowledge of the role of viruses as a cause of cancer has led to the development of vaccines to help prevent certain human cancers. But these vaccines can only protect against infections if they are given before the person is exposed to the cancer-promoting virus.
Human papillomaviruses (HPVs) are a group of more than 150 related viruses. They are called papillomaviruses because some of them cause papillomas, which are more commonly known as warts. Some types of HPV only grow in skin, while others grow in mucous membranes such as the mouth, throat, or vagina.
All types of HPV are spread by contact (touch). More than 40 types of HPV can be passed on through sexual contact. Most sexually active people are infected with one or more of these HPV types at some point in their lives. At least a dozen of these types are known to cause cancer.
While HPV infections are very common, cancer caused by HPV is not. Most people infected with HPV will not develop a cancer related to the infection. However, some people with long-lasting infections of high risk types of HPV, are at risk of developing cancer.
HPV infections of the mucous membranes can cause genital warts, but they usually have no symptoms. There are no effective medicines or other treatments for HPV, other than removing or destroying cells that are known to be infected. But in most people, the body’s immune system controls the HPV infection or gets rid of it over time. To learn more, see HPV and HPV Testing.
A few types of HPV are the main causes of cervical cancer, which is the second most common cancer among women worldwide. Cervical cancer has become much less common in the United States because the Pap test has been widely available for many years. This test can show pre-cancer in cells of the cervix that might be caused by HPV infection. These pre-cancer cells can then be destroyed or removed, if needed. This can keep cancer from developing.
Doctors can now also test for HPV as part of cervical cancer screening, which can tell them if someone might be at higher risk for cervical cancer. Nearly all individuals with cervical cancer show signs of HPV infection on lab tests. Even though doctors can test people with a cervix for HPV, there is no treatment directed at HPV itself. But there is a vaccine that can help prevent it. If the HPV causes abnormal cells to start growing, these cells can be removed or destroyed.
See HPV and HPV Testing for more information on this topic.
Smoking, which is also linked with these cancers, may work with HPV to increase cancer risk. Other genital infections may also increase the risk that HPV will cause cancer.
You can get more details in HPV and Cancer.
Vaccines are now available to help protect children and young adults against infection from the main cancer-causing HPV types. HPV vaccination can help prevent more than 90% of HPV cancers. These vaccines are approved for use in females and males and are given as a series of injections (shots).
The vaccines can only be used to help prevent HPV infection – they do not stop or help treat an existing infection. To be most effective, the vaccine series should be given before a person becomes sexually active (has sex with another person).
American Cancer Society recommendations for HPV vaccination
See HPV Vaccines for more on this.
EBV is a type of herpes virus. It is probably best known for causing infectious mononucleosis, often called “mono” or the “kissing disease.” In addition to kissing, EBV can be passed from person to person by coughing, sneezing, or by sharing drinking or eating utensils. Most people in the United States are infected with EBV by the end of their teen years, although not everyone develops the symptoms of mono.
As with other herpes virus infections, EBV infection is life-long, even though most people have no symptoms after the first few weeks. EBV infects and stays in certain white blood cells in the body called B lymphocytes (also called B cells). There are no medicines or other treatments to get rid of EBV, nor are there vaccines to help prevent it, but EBV infection doesn’t cause serious problems in most people.
EBV infection increases a person’s risk of getting nasopharyngeal cancer (cancer of the area in the back of the nose) and certain types of fast-growing lymphomas such as Burkitt lymphoma. It may also be linked to Hodgkin lymphoma and some cases of stomach cancer. EBV-related cancers are more common in Africa and parts of Southeast Asia. Overall, very few people who have been infected with EBV will ever develop these cancers.
Both HBV and HCV cause viral hepatitis, a type of liver infection. Other viruses can also cause hepatitis (hepatitis A virus, for example), but only HBV and HCV can cause the long-term (chronic) infections that increase a person’s chance of liver cancer. In the United States, less than half of liver cancers are linked to HBV or HCV infection. But this number is much higher in some other countries, where both viral hepatitis and liver cancer are much more common. Some research also suggests that long-term HCV infection might be linked with some other cancers, such as non-Hodgkin lymphoma.
HBV and HCV are spread from person to person in much the same way as HIV (see the section on HIV below) — through sharing needles (such as during injection drug use), unprotected sex, or childbirth. They can also be passed on through blood transfusions, but this is rare in the United States because donated blood is tested for these viruses.
Of the 2 viruses, infection with HBV is more likely to cause symptoms, such as a flu-like illness and jaundice (yellowing of the eyes and skin). Most adults recover completely from HBV infection within a few months. Only a very small portion of adults go on to have chronic HBV infections, but this risk is higher in young children. People with chronic HBV infections have a higher risk for liver cancer.
HCV is less likely to cause symptoms than HBV, but it is more likely to cause chronic infection, which can lead to liver damage or even cancer. Millions of people in the United States have chronic HCV infections, and most of these people don’t even know they have it. To help find some of these unknown infections, the US Centers for Disease Control and Prevention (CDC) recommends that all people 18 years of age or older get tested for HCV at least once, and that some groups of people get tested more often. (For a more complete list of who should get tested for HCV and how often, visit the CDC website at: https://www.cdc.gov/hepatitis/hcv/cfaq.htm.)
Once an infection is found, treatment and preventive measures can be used to slow liver damage and reduce cancer risk. Both hepatitis B and C infections can be treated with drugs. Treating chronic hepatitis C infection with a combination of drugs for at least a few months can get rid of HCV in many people. A number of drugs can also be used to help treat chronic hepatitis B. Although they don’t cure the disease, they can lower the risk of liver damage and might lower the risk of liver cancer as well.
There is a vaccine to prevent HBV infection, but none for HCV. In the United States, the HBV vaccine is recommended for all children. It’s also recommended for adults up to age 59, as well as those who are older and at risk of HBV exposure. This includes people infected with HIV, men who have sex with men, injection drug users, people in certain group homes, people with certain medical conditions and occupations (such as health care workers), and others. (For a more complete list of who should get the HBV vaccine, visit the CDC website at: https://www.cdc.gov/hepatitis/hbv/bfaq.htm.)
HIV, the virus that causes acquired immune deficiency syndrome (AIDS), doesn’t appear to cause cancers directly. But HIV infection increases a person’s risk of getting several types of cancer, especially some linked to other viruses.
HIV can be spread through semen, vaginal fluids, blood, and breast milk from an HIV-infected person. Known routes of spread include:
HIV is not spread by insects, through water, or by casual contact such as talking, shaking hands, hugging, coughing, sneezing, or from sharing dishes, bathrooms, kitchens, phones, or computers. It is not spread through saliva, tears, or sweat.
HIV infects and destroys white blood cells known as helper T-cells, which weakens the body’s immune system. This might let some other viruses, such as HPV, thrive, which might lead to cancer.
Many scientists believe that the immune system is also important in attacking and destroying newly formed cancer cells. A weak immune system might let new cancer cells survive long enough to grow into a serious, life-threatening tumor.
Other types of cancer that may be more likely to develop in people with HIV infection include:
Some other, less common types of cancer may also be more likely to develop in people with HIV.
Because HIV infection often has no symptoms for years, a person can have HIV for a long time and not know it. The CDC recommends that everyone between the ages of 13 and 64 be tested for HIV at least once as part of their routine health care.
There is no vaccine to prevent HIV. But there are ways to lower your risk of getting it, such as not having unprotected sex or sharing needles with someone who has HIV. For people who are at high risk of HIV infection, such as injection drug users and people whose partners have HIV, taking medicine (as a pill every day) is another way to help lower your risk of infection.
For people already infected with HIV, taking anti-HIV drugs can help slow the damage to the immune system, which may help reduce the risk of getting some of the cancers above.
For more information, see HIV Infection, AIDS, and Cancer.
HHV-8, also known as Kaposi sarcoma–associated herpes virus (KSHV), has been found in nearly all tumors in patients with Kaposi sarcoma (KS). KS is a rare, slow-growing cancer that often appears as reddish-purple or blue-brown tumors just underneath the skin. In KS, the cells that line blood and lymph vessels are infected with HHV-8. The infection makes them divide too much and live longer than they should. These types of changes may eventually turn them into cancer cells.
HHV-8 is transmitted through sex and appears to be spread other ways, such as through blood and saliva, as well. Studies have shown that fewer than 10% of people in the US are infected with this virus.
HHV-8 infection is life-long (as with other herpes viruses), but it does not appear to cause disease in most healthy people. Many more people are infected with HHV-8 than ever develop KS, so it’s likely that other factors are also needed for it to develop. Having a weakened immune system appears to be one such factor. In the US, almost all people who develop KS have other conditions that have weakened their immune system, such as HIV infection or immune suppression after an organ transplant.
KS was rare in the United States until it started appearing in people with AIDS in the early 1980s. The number of people with KS has dropped in the US since peaking in the early 1990s, most likely because of better treatment of HIV infection.
For more information on KS, see Kaposi Sarcoma.
HHV-8 infection has also been linked to some rare blood cancers, such as primary effusion lymphoma. The virus has also been found in many people with multicentric Castleman disease, an overgrowth of lymph nodes that acts very much like and often develops into cancer of the lymph nodes (lymphoma). Further study is needed to better understand the role of HHV-8 in these diseases.
HTLV-1 has been linked with a type of lymphocytic leukemia and non-Hodgkin lymphoma called adult T-cell leukemia/lymphoma (ATL). This cancer is found mostly in southern Japan, the Caribbean, central Africa, parts of South America, and in some immigrant groups in the southeastern United States.
In addition to ATL, this virus can cause other health problems, although many people with HTLV-1 don’t have any of them.
HTLV-1 belongs to a class of viruses called retroviruses. These viruses use RNA (instead of DNA) for their genetic code. To reproduce, they must go through an extra step to change their RNA genes into DNA. Some of the new DNA genes can then become part of the chromosomes of the human cell infected by the virus. This can change how the cell grows and divides, which can sometimes lead to cancer.
HTLV-1 is something like HIV, which is another human retrovirus. But HTLV-1 cannot cause AIDS. In humans, HTLV-1 is spread in the same ways as HIV, such as unprotected sex with an HTLV-1-infected partner or injection with a needle after an infected person has used it. Mothers infected with HTLV-1 can also pass on the virus to their children, although this risk can be reduced if the mother doesn’t breastfeed.
Infection with HTLV-1 is rare in the United States. Fewer than 1% of people in the US are infected with HTLV-1, but this rate is much higher in groups of people at high risk (such as injection drug users). Since 1988, all blood donated in the United States has been screened for HTLV-1. This has greatly reduced the chance of infection through transfusion, and has also helped control the potential spread of HTLV-1 infection.
Once infected with HTLV-1, a person’s chance of developing ATL can be up to about 5%, usually after a long time with no symptoms (20 or more years).
MCV was discovered in 2008 in samples from a rare and aggressive type of skin cancer called Merkel cell carcinoma. Most people are infected with MCV at some point (often in childhood), and it usually causes no symptoms. But in a few people with this infection, the virus can affect the DNA inside cells, which can lead to Merkel cell cancer. Nearly all Merkel cell cancers are now thought to be linked to this infection.
It is not yet clear how people become infected with this virus, but it has been found in a number of places in the body, including normal skin and saliva.
For more information, see Skin Cancer: Merkel Cell Carcinoma.
SV40 is a virus that usually infects monkeys. Some polio vaccines prepared between 1955 and 1963 were made from monkey cells and were later found to be contaminated with SV40.
Some older studies suggested that infection with SV40 might increase a person’s risk of developing mesothelioma (a rare cancer of the lining of the lungs or abdomen), as well as some brain tumors, bone cancers, and lymphomas. But the accuracy of these older studies has been questioned.
Scientists have found that some lab animals, such as hamsters, developed mesotheliomas when they were intentionally infected with SV40. Researchers have also noticed that SV40 can make mouse cells grown in the lab become cancerous.
Other researchers have studied biopsy specimens of certain human cancers and found fragments of DNA that look like they might be from SV40. But not all researchers have found this, and fragments much like these can also be found in human tissues that show no signs of cancer.
So far, the largest studies looking at this issue have not found any increased risk for mesothelioma or other cancers among people who got the contaminated polio vaccines as children. For example, the recent increase in lung mesothelioma cases has been seen mainly in men aged 75 and older, most of whom would not have received the vaccine. Among the age groups who were known to have gotten the vaccine, mesothelioma rates have actually gone down. And even though women were just as likely to have had the vaccine, many more men continue to be diagnosed with mesothelioma.
The bottom line: even though SV40 causes cancer in some lab animals, the evidence so far suggests that it does not cause cancer in humans.
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
Armstrong GL, Wasley A, Simard EP, et al. The prevalence of Hepatitis C Virus infection in the United States, 1999 through 2002. Ann Int Med. 2006;144;705–714.
Ault KA. Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol. 2006;Suppl:40470.
Bialasiewicz S, Lambert SB, Whiley DM, et al. Merkel cell polyomavirus DNA in respiratory specimens from children and adults. Emerg Infect Dis [serial on the Internet]. 2009 Mar. Accessed at wwwnc.cdc.gov/eid/article/15/3/08-1067_article on October 22, 2014.
Bonnet F, Lewden C, May T, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer. 2004;101:317–324.
Borges JD, Souza VA, Giambartolomei C, et al. Transmission of human herpesvirus type 8 infection within families in American indigenous populations from the Brazilian Amazon. J Infect Dis. 2012;205:1869-1876.
Buchschacher GL Jr, Wong-Staal F. RNA Viruses. In DeVita VT, Lawrence TS, Rosenberg SA (eds). Cancer: Principles & Practice of Oncology, 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011: 186–192.
Caskey MF, Morgan DJ, Porto AF, et al. Clinical manifestations associated with HTLV type I infection: a cross-sectional study. AIDS Res Hum Retroviruses. 2007;23:365−371.
Centers for Disease Control and Prevention. Hepatitis B Questions and Answers for the Public. 2022. Accessed at https://www.cdc.gov/hepatitis/hbv/bfaq.htm on March 31, 2022.
Centers for Disease Control and Prevention. Hepatitis C Information for Health Professionals. 2022. Accessed at https://www.cdc.gov/hepatitis/HCV/HCVfaq.htm on March 31, 2022.
Centers for Disease Control and Prevention. HIV transmission through transfusion ---Missouri and Colorado, 2008. Morb Mort Wkly Rep. 2010;59(41)1335-1339.
Chen T, Hedman L, Mattila PS, Serological evidence of Merkel cell polyomavirus primary infections in childhood. J Clin Virol. 2011;50:125−129.
Chen T, Hudnall SD. Anatomical mapping of human herpesvirus reservoirs of infection. Modern Pathology. 2006;19:726–737.
Cote TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin’s lymphoma among people with AIDS: incidence, presentation and public health burden. Int J Cancer. 1997;73:645–650.
Engels EA, Atkinson JO, Graubard BI, et al. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis. 2007;196:199−207.
Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096–1100.
Fontham, ETH, Wolf, AMD, Church, TR, et al. Cervical Cancer Screening for Individuals at Average Risk: 2020 Guideline Update from the American Cancer Society. CA Cancer J Clin. 2020. https://doi.org/10.3322/caac.21628.
Howley PM, Ganem D, Kieff E. DNA Viruses. In DeVita VT, Lawrence TS, Rosenberg SA (eds). Cancer: Principles & Practice of Oncology, 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011: 173−185.
Lanoy E, Dores GM, Madeleine MM, et al. Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. AIDS. 2009;23:385–393.
Lambert PF, Sugden B. Chapter 11: Viruses and Human Cancer. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa. Elsevier: 2014.
Manfredi JJ, Dong J, Liu WJ, et al. Evidence against a role for SV40 in human mesothelioma. Cancer Research. 2005;65:2602–2609.
Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001;344:1125–1131.
Nagachinta T, Duerr A, Suriyanon V, et al. Risk factors for HIV-1 transmission from HIV-seropositive male blood donors to their regular female partners in northern Thailand. AIDS. 1997;11:1765–1772.
National Cancer Institute. HIV Infection and Cancer Risk. 2011. Accessed at www.cancer.gov/cancertopics/factsheet/Risk/hiv-infection on September 22, 2014.
National Cancer Institute. HPV and Cancer. 2012. Accessed at www.cancer.gov/cancertopics/factsheet/Risk/HPV on September 22, 2014.
National Cancer Institute. Simian Virus 40 and Human Cancer: Fact Sheet. Accessed at www.cancer.gov/cancertopics/factsheet/simian-virs-40 on August 29, 2011. Content no longer available.
National Cancer Institute. Studies find no evidence that SV40 is related to human cancer. Accessed at www.cancer.gov/newscenter/newsfromnci/2004/sv40 on September 22, 2014.
Poiesz BJ, Papsidero LD, Ehrlich G, et al. Prevalence of HTLV-I-associated T-cell lymphoma. Am J Hematol. 2001;66:32–38.
Qu L, Jenkins F, Triulzi DJ. Human herpesvirus 8 genomes and seroprevalence in United States blood donors. Transfusion. 2010;50:1050–1056.
Rodig SJ, Cheng J, Wardzala J, et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest. 2012;122:4645-4653.
Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2012;118:6226–6233.
Smith BD, Morgan RL, Beckett GA, et al; Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012 Aug 17;61(RR-4):1–32.
Strickler HD, Goedert JJ, Devesa SS, et al. Trends in U.S. pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines. J Natl Cancer Inst. 2003;95:38–45.
Vilchez RA, Kozinetz CA, Butel JS. Conventional epidemiology and the link between SV40 and human cancers. Lancet Oncol. 2003;4:188–191.
Last Revised: March 31, 2022